Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Attachment How does NCX 470's efficacy and safety profile compare to existing glaucoma treatments and potential market share? What are the expected regulatory timelines for FDA approval following the Denali trial? How will the positive Phase 3 results affect NICX's upcoming earnings and stock valuation? Clinical trials 13 days ago Read more globenewswire
Nicox Extends Existing Flexible Equity Financing What are the covenants or terms attached to the extended financing that could affect future financing flexibility? How might this financing extension influence market perception of NICX's financial health and risk profile? Will the extended financing provide sufficient runway for NICX's upcoming R&D and commercial milestones? Financing 26 days ago Read more globenewswire